Gen-Probe Incorporated http://www.alacrastore.com/company-snapshot/Gen_Probe_Incorporated-2514483 Saturday, July 05, 2008 4:55:45 PM 2514483 Gen-Probe Incorporated en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/T1860581ccbn/T1860581norm... - William Blair & Company - AnalystWhy don't we go ahead and get started. Good afternoon; my name is Brian Weinstein, and I cover Gen-Probe here at William Blair & Co. I'm required to inform you that for a complete list of research disclosures for potential conflicts of interest, you should visit our website at www.williamblair.com. The breakout for this presentation will take place in the Conservatory, which is located on the seventh floor. Quickly on Gen-Probe, we launched coverage just last week with an extensive report, which is available on the eighth floor. We view Gen-Probe as a franchise name in the molecular diagnostics space, which is the fastest-growing area of the overall diagnostics industry. But with the Company's two existing businesses represent solid, low double digit growers, while the pipeline offers the potential for entering important new markets over the coming years. In addition, the Company has a very solid financial position that gives Management flexibility... 6/18/2008 7:10:00 PMGen-Probe54.0000FinalGen-Probe at William Blair & Company Growth Stock Conference TranscriptGPRO1:10pm CTTranscriptT1860581Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1846260ccbn/T1846260norm... - Needham & Company - AnalystGood morning. I'm Ed Shenkan. I cover medical devices and diagnostics at Needham. It's a pleasure to introduce Gen-Probe. We have Herm Rosenman, Senior Vice President and Chief Financial Officer. ... 6/11/2008 2:09:00 PMGen-Probe54.0000FinalGen-Probe at Needham & Company Biotechnology and Medical Technology Conference TranscriptGPRO11:00am ETTranscriptT1846260Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0001-25775869newstex/PRN-0001-25775869xml QUEBEC CITY, Jun. #, #### (Canada NewsWire Group delivered by Newstex) -- /CNW Telbec/ -- DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced...0700000007001000070010040701400007014008040000000401600004016048040160186/5/2008 7:07:29 AM180000001800400018008000190000001900200019002012Canada NewsWire GroupPRN-0001-25775869DIAGNOCURE INCGEN PROBE INCCURGPRONewsNewstexBELGIUM - Gen-Probe Inc of the US launched a challenging tender offer to acquire the entire ordinary share capital of Innogenetics NV (IN), a Gent-based biotechnological company, for #.# euros ($#.### US) in cash per share, or a total value of ###.### mil euros ($###.### mil). The offer was conditioned upon at least ##% shares being tendered. The transaction was subject to regulatory approvals. Previously, Solvay Pharmaceuticals SA (SP), a unit of Solvay SA, planned to launch a tender offer to acquire the remaining ##.##% interest, or ##.### mil ordinary shares, which it did not already own, in IN.6/4/2008 10:19:55 AM36866T45763R36866T45763RGen-Probe IncInnogenetics NVGen-Probe IncInnogenetics NVhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Gen_Probe_Inc_launches_a_tender_offer_for_Innogenetics_NV-1983210040sdc/19832100401983210040Copyright © 2008, Thomson Financial, All Rights ReservedNasdaqDrugsUnited StatesBiological products, except diagnostic substances2836CACaliforniaPublicGPRO2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizationsCooley Godward LLPLinklatersEuronext BDrugsBelgiumBiological products, except diagnostic substances2836FFForeignPublicINNX2511003Biotech coBiotech coCashCash OnlyOrdinary Share169781003Jun 4 20081.3210034.27900-5.30200-5.30200-24.46800-19.14600-8.72400-10.2740040.810000.734001.82400-21.32600-0.81800-25.37200-25.1250079.0280014.50100153.19800EUR31 Mar 080.0000096.610000.00000424.52600837.60600EURO31 Dec 0731 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.460001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.00000Gen-Probe Inc is abiotechnology company,headquartered in San Diego,California, focused on thedevelopment, manufacture andmarketing of nucleic acidtests (NATs) used primarily todiagnose human diseases andscreen donated human blood.The company was founded in1985.Gen-Probe Inc is a biotechnology company, headquartered inSan Diego, California, focused on the development,manufacture and marketing of nucleic acid tests (NATs) usedprimarily to diagnose human diseases and screen donatedhuman blood. The company was founded in 1985.Gen-Probe Inc is a biotechnology company, headquartered in San Diego, California, focused on the development, manufacture and marketing of nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. The company was founded in 1985.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.00000Innogenetics NV, based inGent, Belgium, is abiotechnological company thatdevelops and wholesalesdiagnostic products to improvetherapy management and patienthealth. Its diagnostic assaysfocus on molecular diagnosticsand multiparameter testing.The company was founded in1985.Innogenetics NV, based in Gent, Belgium, is abiotechnological company that develops and wholesalesdiagnostic products to improve therapy management andpatient health. Its diagnostic assays focus on moleculardiagnostics and multiparameter testing. The company wasfounded in 1985.Innogenetics NV, based in Gent, Belgium, is a biotechnological company that develops and wholesales diagnostic products to improve therapy management and patient health. Its diagnostic assays focus on molecular diagnostics and multiparameter testing. The company was founded in 1985.0.000000.000000.0000030.88000YEURO03 Jun 08Tue, 03 Jun 2008 00:00:00 ESTDate Announced: 06/03/2008Date Effective:MergerFriendlyPending0.000000.000000.00000215.854000.000006.10000Price/Share0.00000188.361 EURO188.36100188.36100215.854 EURO215.854000.000000.000009.481009.48100215.85400215.854 EURO1.55400N148.865000.000000.000000.000000.000000.00000292.75900292.75900-51.87600-59.44800-14.77800-12.422003.988000.000000.00000100.00000-59.44800-14.778007.72300-12.422003.98800-15.70600-10.840003.480000.000000.000000.000000.52000335.490000.000000.0000059.920000.0000040.81000-34.82400-12.929000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.00000BELGIUM - Gen-Probe Inc of theUS launched a challengingtender offer to acquire theentire ordinary share capitalof Innogenetics NV (IN), aGent-based biotechnologicalcompany, for 6.1 euros ($9.481US) in cash per share, or atotal value of 188.361 mileuros ($292.759 mil). Theoffer was conditioned upon atleast 90% shares beingtendered. The transaction wassubject to regulatoryapprovals. Previously, SolvayPharmaceuticals SA (SP), aunit of Solvay SA, planned tolaunch a tender offer toacquire the remaining 93.23%interest, or 28.788 milordinary shares, which it didnot already own, in IN.BELGIUM - Gen-Probe Inc of the US launched a challenging tender offer to acquire the entire ordinary share capital of Innogenetics NV (IN), a Gent-based biotechnological company, for 6.1 euros ($9.481 US) in cash per share, or a total value of 188.361 mil euros ($292.759 mil). The offer was conditioned upon at least 90% shares being tendered. The transaction was subject to regulatory approvals. Previously, Solvay Pharmaceuticals SA (SP), a unit of Solvay SA, planned to launch a tender offer to acquire the remaining 93.23% interest, or 28.788 mil ordinary shares, which it did not already own, in IN.BELGIUM - Gen-Probe Inc of the US launched a challenging tender offer to acquire theentire ordinary share capital of Innogenetics NV (IN), a Gent-based biotechnologicalcompany, for 6.1 euros ($9.481 US) in cash per share, or a total value of 188.361 mileuros ($292.759 mil). The offer was conditioned upon at least 90% shares being tendered.The transaction was subject to regulatory approvals. Previously, Solvay Pharmaceuticals SA(SP), a unit of Solvay SA, planned to launch a tender offer to acquire the remaining93.23% interest, or 28.788 mil ordinary shares, which it did not already own, in IN.BELGIUM - Gen-Probe Inc of the US launched a challenging tender offer to acquire the entire ordinary share capital of Innogenetics NV (IN), a Gent-based biotechnological company, for 6.1 euros ($9.481US) in cash per share, or a total value of 188.361 mil euros ($292.759 mil). The offer was conditioned upon at least 90% shares being tendered. The transaction was subject to regulatory approvals.Previously, Solvay Pharmaceuticals SA (SP), a unit of Solvay SA, planned to launch a tender offer to acquire the remaining 93.23% interest, or 28.788 mil ordinary shares, which it did not already own,in IN.BELGIUM - Gen-Probe Inc of the US launched a challenging tender offer to acquire the entire ordinary share capital of Innogenetics NV(IN), a Gent-based biotechnological company, for 6.1 euros ($9.481 US) in cash per share, or a total value of 188.361 mil euros ($292.759mil). The offer was conditioned upon at least 90% shares being tendered. The transaction was subject to regulatory approvals. Previously,Solvay Pharmaceuticals SA (SP), a unit of Solvay SA, planned to launch a tender offer to acquire the remaining 93.23% interest, or 28.788mil ordinary shares, which it did not already own, in IN.$ 335.490 - UBS Investment Bank - Adv0.00000UBS Investment Bank1.00000Credit Suisse Group1.00000$ 335.490 - Credit Suisse Group - Adv0.00000Pending779.5780096.61000424.52600837.606000.90500-3.63100-3.63100-16.75800-13.11300-5.97500-7.0370027.95100-14.60600-0.56000-0.810000.000000.000000.00000-0.5600027.9510027.9510040.3220065.8000034.9800048.63000-17.37700-25.05700-21.11500-13.64600-14.01200-17.37700-17.20800-24.97300-20.75300-13.62300-13.89700-17.2080054.1260053.745000.0000071.0550065.1750054.12600104.92500104.92500105.58400139.34400100.21700111.41400Status:PendingEUR-10.89300nm0.000006.740006.7400.000000.000000.000000.00000-4.5380040.81000-13.22500-1.489000.00000-12.896006.739002836:Biological products, except diagnostic substances5047:Medical, dental, and hospital equipment & supplies8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations2511003NasdaqUnited States2836CaliforniaPublicGPRO2836:Biological products, except diagnostic substances5047:Medical, dental, and hospital equipment & supplies8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations169781003Euronext BBelgium2836ForeignPublicINNX292.75900215.85400335.49000170.59400Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/B1868262ccbn/B1868262norm...GPRO proposed an acquisition of Innogenetics and launched cash tender offer to acquire all outstanding shares of Innogenetics for EUR#.# per share, roughly EUR###m in equity value. ... 6/3/2008 1:12:00 PMGen-Probe54.0000EditedGen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics SummaryGPRO8:30am ETBriefB1868262Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1868262ccbn/T1868262norm...Welcome, and thank you for standing by. At this time all participants are in a listen-only mode. After the presentation we will conduct a question-and-answer session. (OPERATOR INSTRUCTIONS). Today's conference is being recorded, and if you have any objections, you may disconnect at this time. I would now like to turn the meeting over to Mr. Mike Watts. Sir, you may begin. ... 6/3/2008 1:12:00 PMGen-Probe54.0000FinalGen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics TranscriptGPRO8:30am ETTranscriptT1868262Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0003-25718205newstex/PRN-0003-25718205xml SAN DIEGO, Jun. #, #### (PR Newswire Europe delivered by Newstex) -- - Acquisition Expected to Accelerate Gen-Probe's Commercial Expansion in Fast-Growing European Market; Add Complementary Products, Technologies and Markers - ...04000000040160000401600504016001040160180401604804002000040020010200000002002000020020061300000013002000130020056/3/2008 9:09:02 AM1800000018016000180200001800400019000000190020001900200719002018PR Newswire EuropePRN-0003-25718205GEN PROBE INCHENRY L NORDHOFFGPRONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25716298newstex/PRN-0005-25716298xml SAN DIEGO, Jun. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Gen-Probe Incorporated (Nasdaq: GPRO), a pioneer and leader in nucleic acid diagnostics for human disease, announced today that it has launched a conditional tender...04000000040160000401600504016001040160180401604804002000040020010200000002002000020020061300000013002000130020056/3/2008 8:07:21 AM1800000018016000180200001800400019000000190020001900200719002018PR Newswire USPRN-0005-25716298DIVERSGEN PROBE INCHENRY L NORDHOFFDYI.UNGPRONewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1851082ccbn/T1851082norm... - Robert W. Baird - AnalystGood afternoon. My name is Quintin Lai. I am the Senior Analyst for the Life Science and Diagnostics group for Robert W. Baird. Today, we have the pleasure of having Gen-Probe present at our conference. Gen-Probe is a leading molecular diagnostic Company and today, presenting for the Company, we have the honor of Kevin Herde, Corporate Controller, and Mike Watts, Director of Investor Relations. Thank you. ... 5/14/2008 5:13:00 PMGen-Probe54.0000FinalGen-Probe at Robert W. Baird & Co., Inc. Growth Stock Conference TranscriptGPRO1:20pm CTTranscriptT1851082Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1740149ccbn/T1740149norm... - Banc of America Securities - AnalystNothing like starting out late. As you are aware, we are required to make a number of conflict of interest and related disclosures in connection with our participation in this conference and the companies that we may discuss. If you'd like to review these important disclosures, please pick up the packet containing the public appearance disclosures at the back of this room. PDF copies can be accessed by those of you viewing these presentations via webcast. Good morning; very pleased to have Gen-Probe here with us. Formal presentation from Mike Watts, Director of Investor Relations and Kevin Hardy is here as well, who is the Controller for Q&A; Mike? ... 5/13/2008 3:14:00 PMGen-Probe54.0000FinalGen-Probe at Bank of America Securities Health Care Conference TranscriptGPRO8:00am PTTranscriptT1740149Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1740148ccbn/T1740148norm... - Deutsche Bank - AnalystOkay, good morning everybody. We're pleased next to have with us the Management Team from Gen-Probe. Gen-Probe is a leading molecular diagnostics Company with leading franchises in blood screening and clinical diagnostics, and I think these segments are going to drive some pretty healthy growth over the next several quarters. Additionally, I think one of the main reasons to own Gen-Probe is its pipeline, and here with us from the Company is the Company's CFO, Herm Rosenman and the Company's Senior Director of Investor and Corporate Communications, Mike Watts. So Herm, why don't you please go ahead. ... 5/6/2008 8:13:00 PMGen-Probe54.0000FinalGen-Probe at Deutsche Bank Securities Inc. Health Care Conference TranscriptGPRO11:30am ETTranscriptT1740148Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1816751ccbn/T1816751norm...Great, well, let's go ahead and get started. It's my pleasure to have with me today two members of the management team from Gen-Probe Corporation, both the CFO, Herm Rosenman, and the VP-Investor Relations, Mike Watts -- maybe Senior VP, Mike. Don't come after me! (LAUGHTER) Anyway, Gen-Probe Corporation -- what I'd like to do is talk very briefly about the Company and what I think is most interesting from defining the investment debate, or at least try to. Herm has told me that he would like a more interactive session now. He's blaming me for not having more interactive sessions, so he's going to hold my feet to the fire if you don't ask questions, so I made kind of call people out in a very Socratic method, so beware. So, real quickly on Gen-Probe, for those of you who do not know, Gen-Probe today -- a leader in molecular diagnostics broadly. They really have two independent segments. One I define as clinical diagnostics; the other I define as sort of blood screening. The Company is a... 5/2/2008 6:10:00 PMGen-Probe54.0000FinalGen-Probe at Morgan Stanley 2008 Global Healthcare Unplugged Conference TranscriptGPRO4:20pm ETTranscriptT1816751Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1823008ccbn/B1823008norm...Reacceleration of blood screening business combined with double-digit growth in clinical diagnostics helped Co. set a new record for quarterly product sales, which exceeded $###m for the first time. ... 4/28/2008 10:10:00 PMGen-Probe54.0000EditedQ1 2008 Gen-Probe Earnings Conference Call SummaryGPRO4:30pm ETBriefB1823008Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1823008ccbn/T1823008norm...Welcome, and thank you all for standing by for today's conference. At this time, you lines have been placed in listen-only mode. (OPERATOR INSTRUCTIONS) Today's conference is being recorded. If you have any objections, you may disconnect at this time. Now I would like to turn the conference over to Mr. Mike Watts. Sir, you may begin. ... 4/28/2008 6:12:00 PMGen-Probe54.0000FinalQ1 2008 Gen-Probe Earnings Conference Call TranscriptGPRO4:30pm ETTranscriptT1823008Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-24850686newstex/PRN-0005-24850686xml SAN DIEGO, April ##, Apr. ##, #### (PR Newswire delivered by Newstex) -- SAN DIEGO, April ## /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today reported strong financial results for the first quarter of #### and...11000000110060000400000004016000040160480401600104016018040160030401603104002000040020060401000004010001070000000700100007001004070010020701400007014003070140080200000002002000020020084/28/2008 5:05:36 PM1800000018008000180040001802000018012000180180001900000019001000PR Newswire USPRN-0005-24850686GEN PROBE INCHENRY L NORDHOFFHERM NULL ROSENMANGPRONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-24421964newstex/PRN-0005-24421964xml SAN DIEGO, April ##, Apr. ##, #### (PR Newswire delivered by Newstex) -- SAN DIEGO, April ## /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will release its first quarter #### financial...04000000040160000401600104016048040160184/10/2008 8:05:48 PM180000001800400018008000PR Newswire USPRN-0005-24421964GEN PROBE INCHENRY L NORDHOFFHERM NULL ROSENMANGPRONewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1797475ccbn/T1797475norm... - Leerink Swann - AnalystWe're going to get started with Carl Hull from GPRO. Same format; Carl is going to put up a couple slides and then take any questions you may have out there. ... 4/3/2008 3:11:00 PMGen-Probe54.0000FinalGen-Probe at Leerink Molecular Diagnostics Roundtable Conference TranscriptGPRO1:20pm ETTranscriptT1797475Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1740147ccbn/T1740147norm... - Cowen & Co. - AnalystGood morning. Day three of the conference. I am Sara Michelmore with the medical technology group here. It is my pleasure to introduce to you this morning Gen-Probe. Presenting on behalf of the Company, we have Chief Operating Officer, Carl Hull and Mike Watts from Investor Relations is also here with us today. Carl is going to make his remarks and, time permitting, take a few questions in the room here, and then we do have a breakout session immediately following this presentation, and today, it is going to be upstairs. So if you're interested in the breakout, you can just kind of follow the crowd after the session. With that, I will introduce Carl. Thank you. ... 3/19/2008 10:12:00 AMGen-Probe54.0000FinalGen-Probe at Cowen and Company Health Care Conference TranscriptGPRO8:00am ETTranscriptT1740147Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1740146ccbn/T1740146norm... - Lehman Brothers - AnalystOkay, let's get started. My name is David Chung, and I'm a healthcare analyst at Lehman Brothers. I'm pleased to introduce Carl Hull, President and Chief Operating Officer of Gen-Probe. After his prepared remarks, we'll have a breakout session for Q&A at Periwinkle upstairs. ... 3/18/2008 7:11:00 PMGen-Probe54.0000FinalGen-Probe at Lehman Brothers Healthcare Conference TranscriptGPRO3:15pm ETTranscriptT1740146Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1740144ccbn/T1740144norm...Good morning. Our next presenter is going to be Gen-Probe which is a leading molecular diagnostics company with leading franchises in the STD diagnostics and blood screening markets as well as a broad pipeline of product candidates that target a number of large markets including cancer diagnostics and industrial microbiology testing. With us today from Gen-Probe via webcast is Mike Watts, the Company's Senior Director of corporate communications and Investor Relations. We will begin with a presentation from Mike followed by a question and answer session. Mike, good morning, please go ahead. ... 2/15/2008 6:15:00 PMGen-Probe54.0000FinalGen-Probe at Deutsche Bank Small- and Mid-Cap Growth Conference TranscriptGPRO10:00am ETTranscriptT1740144Credit & Investment ResearchThomson Street Events